FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281652018> ?p ?o ?g. }

• W4281652018 endingPage "8524" @default.
• W4281652018 startingPage "8524" @default.
• W4281652018 abstract "8524 Background: Lurbinectedin, a selective inhibitor of oncogenic transcription, received accelerated approval from the US FDA in June 2020 as monotherapy (3.2 mg/m 2 IV every 21 days) for adults with metastatic SCLC with disease progression on or after platinum-based chemotherapy. This approval was based on the overall response rate (35.2%) and duration of response (DOR; 5.3 months) observed in 105 patients from a phase 2 trial. The ATLANTIS trial (NCT02566993) investigated the combination of lurbinectedin 2.0 mg/m 2 IV + doxorubicin (DOX) 40.0 mg/m 2 IV versus topotecan or CAV. This post hoc analysis explored the efficacy and safety of single-agent lurbinectedin in patients who completed 10 cycles of the combination and then switched to lurbinectedin monotherapy per protocol. Methods: Eligible patients were ≥18 years of age with limited-stage or extensive-stage SCLC, 1 prior line of platinum-based chemotherapy (PD-1/PD-L1 inhibitors were also permitted), ECOG PS ≤2, and chemotherapy-free interval ≥30 days. Tumor assessments were per an independent review committee (IRC). Results: Patients who completed 10 cycles of lurbinectedin + DOX and switched to lurbinectedin monotherapy (n = 50) had a median age of 61.5 years (range: 43, 77); 62% were male; and 100% had an ECOG PS < 2. The overall median number of cycles was 15 (range: 11, 47) and included a median of 5 (1, 37) cycles on monotherapy. The majority of patients who switched to lurbinectedin monotherapy maintained or improved their tumor response (Table). All 3 patients who achieved a complete response (CR) on combination therapy maintained their CR on monotherapy. Of the 26 patients with a partial response (PR) on combination therapy, 3 (12%) achieved a CR and 15 (58%) maintained their PR. Of the 19 patients with stable disease (SD) on combination therapy, 3 (16%) improved from SD to PR (n = 2) or CR (n = 1) and 8 (42%) maintained SD. The median DOR was 8.3 months (95% CI: 7.1, 11.0). The median overall survival (OS) was 20.7 months (95% CI: 15.7, 24.8). Grade 3/4 hematologic abnormalities based on laboratory assessment included lymphopenia (36%), anemia (16%), thrombocytopenia (12%), neutropenia (12%), and leukopenia (10%). Febrile neutropenia was reported in 4% of patients. Conclusions: Patients with relapsed SCLC in ATLANTIS who completed 10 cycles of lurbinectedin + DOX combination and switched to lurbinectedin monotherapy tended to maintain or improve their tumor response (including an increase in CRs), with favorable OS and DOR and acceptable tolerability with no new safety signals. Clinical trial information: NCT02566993. [Table: see text]" @default.
• W4281652018 created "2022-06-13" @default.
• W4281652018 creator A5007163286 @default.
• W4281652018 creator A5014364032 @default.
• W4281652018 creator A5015800207 @default.
• W4281652018 creator A5031841276 @default.
• W4281652018 creator A5033487028 @default.
• W4281652018 creator A5045959269 @default.
• W4281652018 creator A5048766168 @default.
• W4281652018 creator A5052183772 @default.
• W4281652018 creator A5052765751 @default.
• W4281652018 creator A5055278162 @default.
• W4281652018 creator A5083698345 @default.
• W4281652018 creator A5087139362 @default.
• W4281652018 creator A5089042997 @default.
• W4281652018 date "2022-06-01" @default.
• W4281652018 modified "2023-10-18" @default.
• W4281652018 title "Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial." @default.
• W4281652018 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.8524" @default.
• W4281652018 hasPublicationYear "2022" @default.
• W4281652018 type Work @default.
• W4281652018 citedByCount "2" @default.
• W4281652018 countsByYear W42816520182023 @default.
• W4281652018 crossrefType "journal-article" @default.
• W4281652018 hasAuthorship W4281652018A5007163286 @default.
• W4281652018 hasAuthorship W4281652018A5014364032 @default.
• W4281652018 hasAuthorship W4281652018A5015800207 @default.
• W4281652018 hasAuthorship W4281652018A5031841276 @default.
• W4281652018 hasAuthorship W4281652018A5033487028 @default.
• W4281652018 hasAuthorship W4281652018A5045959269 @default.
• W4281652018 hasAuthorship W4281652018A5048766168 @default.
• W4281652018 hasAuthorship W4281652018A5052183772 @default.
• W4281652018 hasAuthorship W4281652018A5052765751 @default.
• W4281652018 hasAuthorship W4281652018A5055278162 @default.
• W4281652018 hasAuthorship W4281652018A5083698345 @default.
• W4281652018 hasAuthorship W4281652018A5087139362 @default.
• W4281652018 hasAuthorship W4281652018A5089042997 @default.
• W4281652018 hasConcept C126322002 @default.
• W4281652018 hasConcept C141071460 @default.
• W4281652018 hasConcept C143998085 @default.
• W4281652018 hasConcept C2776694085 @default.
• W4281652018 hasConcept C2781209748 @default.
• W4281652018 hasConcept C31760486 @default.
• W4281652018 hasConcept C535046627 @default.
• W4281652018 hasConcept C67761136 @default.
• W4281652018 hasConcept C71924100 @default.
• W4281652018 hasConceptScore W4281652018C126322002 @default.
• W4281652018 hasConceptScore W4281652018C141071460 @default.
• W4281652018 hasConceptScore W4281652018C143998085 @default.
• W4281652018 hasConceptScore W4281652018C2776694085 @default.
• W4281652018 hasConceptScore W4281652018C2781209748 @default.
• W4281652018 hasConceptScore W4281652018C31760486 @default.
• W4281652018 hasConceptScore W4281652018C535046627 @default.
• W4281652018 hasConceptScore W4281652018C67761136 @default.
• W4281652018 hasConceptScore W4281652018C71924100 @default.
• W4281652018 hasFunder F4320327811 @default.
• W4281652018 hasIssue "16_suppl" @default.
• W4281652018 hasLocation W42816520181 @default.
• W4281652018 hasOpenAccess W4281652018 @default.
• W4281652018 hasPrimaryLocation W42816520181 @default.
• W4281652018 hasRelatedWork W152753223 @default.
• W4281652018 hasRelatedWork W1831044128 @default.
• W4281652018 hasRelatedWork W1978427220 @default.
• W4281652018 hasRelatedWork W2032110158 @default.
• W4281652018 hasRelatedWork W2329101726 @default.
• W4281652018 hasRelatedWork W2341475099 @default.
• W4281652018 hasRelatedWork W2398512541 @default.
• W4281652018 hasRelatedWork W2528167051 @default.
• W4281652018 hasRelatedWork W83619925 @default.
• W4281652018 hasRelatedWork W2188607138 @default.
• W4281652018 hasVolume "40" @default.
• W4281652018 isParatext "false" @default.
• W4281652018 isRetracted "false" @default.
• W4281652018 workType "article" @default.